Clinical DevelopmentLast reviewed April 2026

Pharmacodynamics(PD)

The study of a drug's biochemical and physiological effects on the body and the mechanisms underlying those effects.

Usage Examples

The Phase 1 study characterized PK/PD with target engagement measured via receptor occupancy imaging.
Exposure-response analysis supported the label recommendation for dose adjustment in moderate hepatic impairment.

What is PD?

Pharmacodynamics (PD) characterizes what the drug does to the body — the biological, biochemical, and physiological effects it produces and the mechanisms underlying those effects. PD endpoints include direct biomarkers (target engagement, receptor occupancy, enzyme inhibition), intermediate biomarkers (physiological changes), and clinical endpoints (symptom improvement, disease progression).

PD data supports dose selection decisions, dose-response modeling, and understanding of drug class effects. Exposure-response analysis (relating PK exposure to PD response) is a core regulatory analysis that informs the label dosing recommendations and identifies populations requiring dose adjustment. FDA reviewers evaluate PK/PD together — sufficient exposure without PD response questions clinical benefit; insufficient exposure despite apparent response raises confounding concerns.

Regulatory Context

This term appears most often in clinical development workflows where submission quality, regulatory evidence, and audit readiness depend on consistent language. It is commonly referenced alongside ICH E4, ICH E7, FDA EXPOSURE RESPONSE.

FDAEMAPMDA

When This Matters

The Phase 1 study characterized PK/PD with target engagement measured via receptor occupancy imaging.
Exposure-response analysis supported the label recommendation for dose adjustment in moderate hepatic impairment.

Common Mistakes

Applying one-region clinical assumptions to global submission strategies.
Missing protocol-to-regulation traceability for pivotal studies.
Underestimating how regional guidance updates impact trial documentation.

Related Regulations

ICH E4ICH E7FDA EXPOSURE RESPONSE

Frequently Asked Questions

PK: what the body does to the drug (absorption, distribution, metabolism, excretion). PD: what the drug does to the body (biological effects, target engagement, clinical response). PK/PD are analyzed together to link drug exposure to biological or clinical effects.

Often yes in early development, but clinical endpoints (symptom improvement, disease progression) remain the ultimate PD measure. Biomarkers accelerate dose-finding; clinical endpoints confirm the drug produces the intended patient benefit.

Statistical relationship between PK exposure (Cmax, AUC) and PD response (efficacy, safety). FDA requires exposure-response analysis to inform dosing recommendations, especially for narrow-therapeutic-index drugs or products where PK varies substantially across populations.